Literature DB >> 2154508

Na+/H+ antiporter is the primary proton transport system used by osteoclasts during bone resorption.

T J Hall1, T J Chambers.   

Abstract

We have examined the effects of inhibitors of proton transport systems on osteoclastic bone resorption using an in vitro bone slice assay, where osteoclasts (OCs) are free from the influence of other bone cells. Amiloride (AM) and dimethylamiloride (DMA), inhibitors of the Na+/H+ antiporter, were potent inhibitors of bone resorption (IC50 approximately 9 and 0.7 microM for AM and DMA, respectively). Omeprazole (OM), a potent inhibitor of parietal cell K+/H+(-)ATPase, was a poor inhibitor of OC bone resorption (IC50 approximately 100 microM). These results strongly suggest that the Na+/H+ antiporter is the primary proton system used by OCs during bone resorption.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154508     DOI: 10.1002/jcp.1041420227

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

Review 1.  Molecular aspects of osteoclast function.

Authors:  T J Hall; T J Chambers
Journal:  Inflamm Res       Date:  1996-01       Impact factor: 4.575

2.  Carbonic anhydrase II gene transcript in cultured osteoclasts from neonatal rats: effect of calcitonin.

Authors:  M H Zheng; Y Fan; S Wysocki; D J Wood; J M Papadimitriou
Journal:  Cell Tissue Res       Date:  1994-04       Impact factor: 5.249

3.  A comparison of the effects of inhibitors of carbonic anhydrase on osteoclastic bone resorption and purified carbonic anhydrase isozyme II.

Authors:  T J Hall; W Higgins; C Tardif; T J Chambers
Journal:  Calcif Tissue Int       Date:  1991-11       Impact factor: 4.333

4.  A mathematical model of osteoclast acidification during bone resorption.

Authors:  Frank V Marcoline; Yoichi Ishida; Joseph A Mindell; Smita Nayak; Michael Grabe
Journal:  Bone       Date:  2016-09-17       Impact factor: 4.398

5.  Calcitonin inhibits proton extrusion in resorbing rat osteoclasts via protein kinase A.

Authors:  Hiroshi Kajiya; Fujio Okamoto; Hidefumi Fukushima; Koji Okabe
Journal:  Pflugers Arch       Date:  2003-01-14       Impact factor: 3.657

6.  Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment.

Authors:  A Del Fattore; B Peruzzi; N Rucci; I Recchia; A Cappariello; M Longo; D Fortunati; P Ballanti; M Iacobini; M Luciani; R Devito; R Pinto; M Caniglia; E Lanino; C Messina; S Cesaro; C Letizia; G Bianchini; H Fryssira; P Grabowski; N Shaw; N Bishop; D Hughes; R P Kapur; H K Datta; A Taranta; R Fornari; S Migliaccio; A Teti
Journal:  J Med Genet       Date:  2005-08-23       Impact factor: 6.318

7.  Proteomic Changes of Osteoclast Differentiation in Rheumatoid and Psoriatic Arthritis Reveal Functional Differences.

Authors:  Orsolya Tünde Kovács; Eszter Tóth; Olivér Ozohanics; Eszter Soltész-Katona; Nikolett Marton; Edit Irén Buzás; László Hunyady; László Drahos; Gábor Turu; György Nagy
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

8.  Role of Na-H exchangers and vacuolar H+ pumps in intracellular pH regulation in neonatal rat osteoclasts.

Authors:  J H Ravesloot; T Eisen; R Baron; W F Boron
Journal:  J Gen Physiol       Date:  1995-02       Impact factor: 4.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.